NYSEAMERICAN:BPMX - Biopharmx Stock Price, Price Target & More

$0.2226 -0.01 (-4.30 %)
(As of 04/22/2018 04:21 AM ET)
Previous Close$0.2226
Today's Range$0.2220 - $0.2342
52-Week Range$0.10 - $0.90
Volume3.05 million shs
Average Volume13.52 million shs
Market Capitalization$45.42 million
P/E RatioN/A
Dividend YieldN/A
Beta0.43

About Biopharmx (NYSEAMERICAN:BPMX)

Biopharmx logoBioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women's health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia. Its VI2OLET is an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and is clinically demonstrated to alleviate the symptoms associated with FBC, including tenderness, aches and swelling. It is developing BPX02, which is an injectable utilizing biologic materials for aesthetic dermatology applications.

Receive BPMX News and Ratings via Email

Sign-up to receive the latest news and ratings for BPMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNYSEAMERICAN:BPMX
CUSIPN/A
Phone+1-650-8895020

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-20,633.33%
Return on EquityN/A
Return on Assets-387.79%

Miscellaneous

EmployeesN/A
Outstanding Shares190,000,000

How to Become a New Pot Stock Millionaire

Biopharmx (NYSEAMERICAN:BPMX) Frequently Asked Questions

What is Biopharmx's stock symbol?

Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX."

How were Biopharmx's earnings last quarter?

Biopharmx Corp (NYSEAMERICAN:BPMX) issued its quarterly earnings results on Wednesday, September, 13th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.06). The biotechnology company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. View Biopharmx's Earnings History.

When is Biopharmx's next earnings date?

Biopharmx is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Biopharmx.

What price target have analysts set for BPMX?

3 brokers have issued 12 month price objectives for Biopharmx's stock. Their forecasts range from $1.50 to $3.00. On average, they anticipate Biopharmx's share price to reach $2.50 in the next twelve months. View Analyst Ratings for Biopharmx.

Are investors shorting Biopharmx?

Biopharmx saw a drop in short interest during the month of March. As of March 29th, there was short interest totalling 12,116,761 shares, a drop of 0.1% from the March 15th total of 12,130,469 shares. Based on an average daily trading volume, of 11,538,273 shares, the days-to-cover ratio is currently 1.1 days. Currently, 7.3% of the company's stock are sold short.

Who are some of Biopharmx's key competitors?

Who are Biopharmx's key executives?

Biopharmx's management team includes the folowing people:
  • James R. Pekarsky, Chairman of the Board, Chief Executive Officer (Age 55)
  • Anja B. Krammer, President, Director (Age 47)
  • Gregory David Kitchener, Chief Financial Officer, Executive Vice President - Finance
  • Kin F. Chan Ph.D., Executive Vice President - Research & Development (Age 41)
  • AnnaMarie Daniels, Executive Vice President - Clinical and Regulatory Affairs
  • Stephen Morlock, Independent Director (Age 61)
  • Ping Wang, Independent Director (Age 38)

Has Biopharmx been receiving favorable news coverage?

News stories about BPMX stock have trended somewhat positive on Sunday, Accern reports. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Biopharmx earned a media sentiment score of 0.07 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 45.59 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of Biopharmx?

Shares of BPMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biopharmx's stock price today?

One share of BPMX stock can currently be purchased for approximately $0.2226.

How big of a company is Biopharmx?

Biopharmx has a market capitalization of $45.42 million.

How can I contact Biopharmx?

Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020.


MarketBeat Community Rating for Biopharmx (BPMX)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  123 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  178
MarketBeat's community ratings are surveys of what our community members think about Biopharmx and other stocks. Vote "Outperform" if you believe BPMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Biopharmx (NYSEAMERICAN:BPMX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Biopharmx in the last 12 months. Their average twelve-month price target is $2.50, suggesting that the stock has a possible upside of 1,023.09%. The high price target for BPMX is $3.00 and the low price target for BPMX is $1.50. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.50$2.50$2.50$2.50
Price Target Upside: 1,023.09% upside2,172.73% upside2,172.73% upside777.19% upside

Biopharmx (NYSEAMERICAN:BPMX) Consensus Price Target History

Price Target History for Biopharmx (NYSEAMERICAN:BPMX)

Biopharmx (NYSEAMERICAN:BPMX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
12/8/2017Maxim GroupReiterated RatingBuy$1.50View Rating Details
9/19/2017HC WainwrightReiterated RatingBuy$3.00View Rating Details
6/3/2017Roth CapitalSet Price TargetBuy$3.00View Rating Details
(Data available from 4/22/2016 forward)

Earnings

Biopharmx (NYSEAMERICAN:BPMX) Earnings History and Estimates Chart

Earnings by Quarter for Biopharmx (NYSEAMERICAN:BPMX)

Biopharmx (NYSEAMERICAN BPMX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2018        
12/7/2017Q3 2018($0.05)($0.05)$0.03 million$0.02 millionViewN/AView Earnings Details
9/13/2017Q2 2018($0.06)($0.06)$0.02 million$0.02 millionViewN/AView Earnings Details
6/13/2017Q1 2018($0.07)($0.07)$0.03 million$0.02 millionViewN/AView Earnings Details
3/23/2017Q4 2017($0.09)($0.09)$0.04 million$0.02 millionViewN/AView Earnings Details
12/13/2016Q3 2017($0.15)($0.13)$0.03 million$0.03 millionViewN/AView Earnings Details
9/12/2016Q2 2017($0.17)($0.18)$0.07 million$0.02 millionViewN/AView Earnings Details
6/14/2016Q117($0.17)($0.16)$0.09 million$0.03 millionViewListenView Earnings Details
4/26/2016Q416($0.17)($0.18)$0.05 million$0.04 millionViewListenView Earnings Details
12/14/2015Q316($0.19)($0.17)$0.02 millionViewN/AView Earnings Details
9/14/2015Q216($0.29)($0.22)$0.01 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Biopharmx (NYSEAMERICAN:BPMX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Biopharmx (NYSEAMERICAN BPMX) Insider Trading and Institutional Ownership History

Insider Trading History for Biopharmx (NYSEAMERICAN:BPMX)

Biopharmx (NYSEAMERICAN BPMX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/7/2018Vivo Capital Viii, LlcMajor ShareholderSell2,000,000$0.36$720,000.00View SEC Filing  
11/24/2017Stephen MorlockDirectorBuy330,000$0.15$49,500.00View SEC Filing  
11/9/2017Vivo Capital Viii, LlcMajor ShareholderSell296,394$0.20$59,278.80View SEC Filing  
8/1/2017Franklin Resources IncMajor ShareholderBuy250,000$0.34$85,000.00View SEC Filing  
4/28/2017Vivo Capital Fund Viii, L.P.Major ShareholderBuy1,282,052$0.78$1,000,000.56View SEC Filing  
11/28/2016Stephen MorlockDirectorBuy428,571$0.35$149,999.85543,956View SEC Filing  
8/15/2016Franklin Resources IncMajor ShareholderBuy484,615$0.65$314,999.75View SEC Filing  
3/29/2016Franklin Resources IncMajor ShareholderBuy540,000$1.20$648,000.00View SEC Filing  
1/14/2016Stephen MorlockDirectorBuy12,000$1.52$18,240.00View SEC Filing  
1/12/2016Stephen MorlockDirectorBuy6,000$1.53$9,180.00View SEC Filing  
1/7/2016Stephen MorlockDirectorBuy5,000$1.47$7,350.00View SEC Filing  
10/15/2015Stephen MorlockDirectorBuy5,000$1.24$6,200.00View SEC Filing  
10/9/2015Stephen MorlockDirectorBuy3,000$1.21$3,630.00223,071View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Biopharmx (NYSEAMERICAN BPMX) News Headlines

Source:
DateHeadline
Biopharmx Corp (BPMX) Sees Significant Drop in Short InterestBiopharmx Corp (BPMX) Sees Significant Drop in Short Interest
www.americanbankingnews.com - April 12 at 2:43 AM
Short Interest in Biopharmx Corp (BPMX) Expands By 16.2%Short Interest in Biopharmx Corp (BPMX) Expands By 16.2%
www.americanbankingnews.com - March 26 at 6:54 PM
BioPharmX (BPMX) Awarded US Patent Protection for Novel Tetracycline-class Topical Drug Compositions - StreetInsider.comBioPharmX (BPMX) Awarded US Patent Protection for Novel Tetracycline-class Topical Drug Compositions - StreetInsider.com
www.streetinsider.com - March 21 at 8:48 AM
Today’s Research Reports on Trending Tickers: BioPharmX and MediWoundToday’s Research Reports on Trending Tickers: BioPharmX and MediWound
finance.yahoo.com - March 21 at 8:48 AM
U.S. Patent and Trademark Office Awards BioPharmX Patent Protection for Novel Tetracycline-class Topical Drug CompositionsU.S. Patent and Trademark Office Awards BioPharmX Patent Protection for Novel Tetracycline-class Topical Drug Compositions
finance.yahoo.com - March 20 at 5:18 PM
BioPharmX to Present at Oppenheimers 28th Annual Healthcare ConferenceBioPharmX to Present at Oppenheimer's 28th Annual Healthcare Conference
finance.yahoo.com - March 14 at 7:07 PM
Biopharmx (BPMX) Set to Announce Quarterly Earnings on WednesdayBiopharmx (BPMX) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - March 14 at 1:16 AM
Biopharmx Corp (BPMX) Short Interest UpdateBiopharmx Corp (BPMX) Short Interest Update
www.americanbankingnews.com - March 10 at 1:48 AM
Biopharmx Corp (BPMX) Major Shareholder Sells $720,000.00 in StockBiopharmx Corp (BPMX) Major Shareholder Sells $720,000.00 in Stock
www.americanbankingnews.com - March 9 at 6:14 PM
Loss-Making BioPharmX Corporation (NYSEMKT:BPMX) Expected To BreakevenLoss-Making BioPharmX Corporation (NYSEMKT:BPMX) Expected To Breakeven
finance.yahoo.com - March 7 at 6:35 PM
BioPharmX to Present at 30th Annual ROTH ConferenceBioPharmX to Present at 30th Annual ROTH Conference
finance.yahoo.com - March 5 at 5:50 PM
Short Interest in Biopharmx Corp (BPMX) Grows By 37.3%Short Interest in Biopharmx Corp (BPMX) Grows By 37.3%
www.americanbankingnews.com - February 27 at 5:58 PM
Biopharmx Corp (BPMX) Sees Large Increase in Short InterestBiopharmx Corp (BPMX) Sees Large Increase in Short Interest
www.americanbankingnews.com - February 9 at 8:28 PM
BioPharmX To Present BPX-04 Rosacea Data At Two Leading Clinical Conferences This MonthBioPharmX To Present BPX-04 Rosacea Data At Two Leading Clinical Conferences This Month
finance.yahoo.com - January 12 at 9:17 AM
Short Interest in Biopharmx Corp (BPMX) Grows By 2.3%Short Interest in Biopharmx Corp (BPMX) Grows By 2.3%
www.americanbankingnews.com - January 10 at 5:38 PM
Biopharmx Corp (BPMX) Short Interest Up 21.9% in DecemberBiopharmx Corp (BPMX) Short Interest Up 21.9% in December
www.americanbankingnews.com - December 27 at 6:40 PM
How Do Analysts See BioPharmX Corporation (NYSEMKT:BPMX) Performing In The Years Ahead?How Do Analysts See BioPharmX Corporation (NYSEMKT:BPMX) Performing In The Years Ahead?
finance.yahoo.com - December 25 at 6:33 PM
ETFs with exposure to BioPharmX Corp. : December 14, 2017ETFs with exposure to BioPharmX Corp. : December 14, 2017
finance.yahoo.com - December 14 at 5:25 PM
BioPharmX Corp. :BPMX-US: Earnings Analysis: Q3, 2018 By the Numbers : December 13, 2017BioPharmX Corp. :BPMX-US: Earnings Analysis: Q3, 2018 By the Numbers : December 13, 2017
finance.yahoo.com - December 13 at 10:19 AM
Biopharmx (BPMX) Given "Buy" Rating at Maxim GroupBiopharmx (BPMX) Given "Buy" Rating at Maxim Group
www.americanbankingnews.com - December 8 at 10:02 AM
BioPharmX Reports Third Quarter 2018 Financial ResultsBioPharmX Reports Third Quarter 2018 Financial Results
finance.yahoo.com - December 7 at 5:14 PM
BioPharmX Demonstrates Topical Minocycline Gel May Exhibit Relevant Antimicrobial and Anti-inflammatory Properties for the Treatment of Acne at ASCB 2017BioPharmX Demonstrates Topical Minocycline Gel May Exhibit Relevant Antimicrobial and Anti-inflammatory Properties for the Treatment of Acne at ASCB 2017
finance.yahoo.com - December 4 at 9:58 AM
Biopharmx Corp (BPMX) Director Stephen Morlock Acquires 330,000 SharesBiopharmx Corp (BPMX) Director Stephen Morlock Acquires 330,000 Shares
www.americanbankingnews.com - November 27 at 8:40 PM
BRIEF-BioPharmX Corp announces pricing of public offeringBRIEF-BioPharmX Corp announces pricing of public offering
www.reuters.com - November 21 at 8:23 PM
Report: Developing Opportunities within Graphic Packaging Holding, Invitation Home, Teradyne, DeanReport: Developing Opportunities within Graphic Packaging Holding, Invitation Home, Teradyne, Dean
www.nasdaq.com - November 16 at 12:08 PM
Report: Developing Opportunities within Graphic Packaging Holding, Invitation Home, Teradyne, Dean Foods, Valley National, and BioPharmX — Future Expectations, Projections Moving into 2018Report: Developing Opportunities within Graphic Packaging Holding, Invitation Home, Teradyne, Dean Foods, Valley National, and BioPharmX — Future Expectations, Projections Moving into 2018
finance.yahoo.com - November 16 at 12:08 PM

SEC Filings

Biopharmx (NYSEAMERICAN:BPMX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Biopharmx (NYSEAMERICAN BPMX) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.